TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer. Issue 1 (22nd November 2017)

• Record Type: Journal Article
• Authors: Qin, Sisi; Liu, Duan; Kohli, Manish; Wang, Liguo; Vedell, Peter T.; Hillman, David W.; Niu, Nifang; Yu, Jia; Weinshilboum, Richard M.; Wang, Liewei
• Is Part Of: Clinical pharmacology & therapeutics. Volume 104:Issue 1(2018)
• Page Start: 201
• Page End: 210
• Publication Date: 2017-11-22
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.907
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The testis‐specific Y‐encoded‐like protein ( TSPYL ) gene family includes TSPYL1 to TSPYL6 . We previously reported that TSPYL5 regulates cytochrome P450 (CYP) 19A1 expression. Here we show that TSPYLs, especially TSPYL 1, 2, and 4, can regulate the expression of many CYP genes, including CYP17A1, a key enzyme in androgen biosynthesis, and CYP3A4, an enzyme that catalyzes the metabolism of abiraterone, a CYP17 inhibitor. Furthermore, a common TSPYL1 single nucleotide polymorphism (SNP), rs3828743 (G/A) (Pro62Ser), abolishes TSPYL1's ability to suppress CYP3A4 expression, resulting in reduced abiraterone concentrations and increased cell proliferation. Data from a prospective clinical trial of 87 metastatic castration‐resistant prostate cancer patients treated with abiraterone acetate/prednisone showed that the variant SNP genotype (A) was significantly associated with worse response and progression‐free survival. In summary, TSPYL genes are novel CYP gene transcription regulators, and genetic alteration within these genes significantly influences response to drug therapy through transcriptional regulation of CYP450 genes.